JAN 08 | FEB 08 | JUN 08 | JUL 08 | AUG 08 | SEP 08 | OCT 08 | DEC 08
January 2008
Institutional Investor magazine — David Pyott named one of the “Best CEO’s in America.”
Allergan announced the phased closure of its breast implant manufacturing facility in Arklow, Ireland, and the transfer of production to Allergan’s state-of-the-art manufacturing plant in Costa Rica.
February 2008
Institutional Investor magazine — Allergan named “No. 1 Pharmaceutical/Specialty Shareholder Friendly Company.”
June 2008
Allergan received U.S. Food and Drug Administration (FDA) approval of TRIVARIS™ (triamcinolone acetonide injectable suspension), a synthetic glucocorticoid corticosteroid with anti-inflammatory action. This is Allergan’s first product in the retina space resulting from the Company’s strategic focus on the development of therapies for back-of-the-eye diseases.
Subsequent to Allergan’s development and promotion agreement with GlaxoSmithKline (GSK), GSK submitted a supplemental New Drug Application (sNDA) to the Japanese Ministry of Health for BOTOX® (botulinum toxin type A) to treat juvenile cerebral palsy. The product was approved in February 2009.
The Australian Therapeutic Goods Administration (TGA) approved BOTOX® for the treatment of upper limb spasticity associated with juvenile cerebral palsy, expanding the indication to benefit a larger population of pediatric patients suffering from this debilitating neuromuscular condition. BOTOX® had previously been approved in Australia for the treatment of lower limb spasticity associated with juvenile cerebral palsy in 1998.
The Korea Food and Drug Administration approved BOTOX® for the treatment of post-stroke upper limb spasticity as well as severe primary axillary hyperhidrosis.
Allergan received approval from the Australian TGA and Health Canada for JUVÉDERM® injectable gel with lidocaine, the Company’s next generation hyaluronic acid-based dermal filler product, which incorporates the local anesthetic 0.3% lidocaine for improved patient comfort. Allergan launched the product in Canada in September 2008 and in Australia in early 2009.
July 2008
Allergan acquired ACZONE® (dapsone) gel 5% from QLT Inc. ACZONE®, which Allergan launched in the United States in November 2008, is a new, first-in-class topical treatment for inflammatory acne and the first new molecule in a decade approved by the FDA for this use.
August 2008
Allergan entered into an exclusive license agreement with Asterand plc relating to a series of pre-clinical compounds whereby Allergan obtained the rights to develop and commercialize select compounds to treat diseases of the eye.
September 2008
Allergan completed a top-line analysis of the Company’s two Phase III clinical trials exploring the use of BOTOX® for the prophylactic treatment of headache in adults suffering from chronic migraine — i.e., headaches and/or migraines that occur on 15 or more days each month. Based on the results from the two Phase III trials, Allergan anticipates filing a supplemental Biologics License Application (sBLA) with the FDA for the use of BOTOX® for chronic migraine in mid-2009. BOTOX® is the first therapy being investigated for this debilitating condition which affects between 1.2 million and 3.6 million Americans.1, 2
October 2008
Allergan entered into a strategic collaboration with Clinique Laboratories, LLC, the No. 1 prestige cosmetics brand in the United States, to develop CLINIQUE MEDICAL, a new skin care line that is scientifically designed and clinically proven to complement select in-office aesthetic procedures and available only through physicians’ offices. Allergan announced the nationwide availability of CLINIQUE MEDICAL in the United States in October 2008.
Allergan filed a sBLA with the FDA for BOTOX® to treat post-stroke upper limb spasticity, and was subsequently granted priority review.
Allergan filed a premarket approval (PMA) supplement with the FDA for JUVÉDERM® injectable gel with lidocaine.
Allergan completed the initial analysis of data from its Phase III studies of POSURDEX® for the treatment of macular edema associated with retinal vein occlusion. POSURDEX® is a novel bioerodable formulation of dexamethasone in Allergan’s proprietary sustained-release drug delivery system that can be used to locally administer medications to the retina.
Allergan invested in BAROnova, Inc.’s Series B financing to further advance the development of BAROnova’s new non-surgical, non-pharmacologic TransPyloric Shuttle (TPS) weight-loss technology.
Allergan and Spectrum Pharmaceuticals, Inc. signed an exclusive collaboration for the development and commercialization of apaziquone, an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.
MedAdNews — Allergan named “Most Admired Specialty Company.”
December 2008
Allergan received FDA approval of LATISSE™ (bimatoprost ophthalmic solution) 0.03%, a novel treatment to stimulate eyelash growth. LATISSE™ is the first and only science-based treatment approved by the FDA to treat hypotrichosis (another name for having inadequate or not enough eyelashes), enhancing eyelash prominence as measured by increases in length, thickness and darkness of eyelashes.
The Korea Food and Drug Administration approved BOTOX® for the temporary improvement in the appearance of moderate to severe glabellar lines (the vertical frown lines between the eyebrows that look like an “11”).
Allergan closed its Fremont, California, facility which had been dedicated to the production of collagen-based dermal fillers. This product line is being eclipsed by non-animal hyaluronic acid-based dermal fillers, which are produced at the Company’s facility in Pringy, France.
The Orange County Register — Allergan ranked among the 20 Orange County companies selected as “Top Workplaces Among Large Companies.” Companies in this category employ 500 or more people within the United States.
Allergan was ranked number nine in the top 10 leadership category by the S&P 500 in its Carbon Disclosure Leadership Index for Carbon-Intensive Industries.
Allergan was recognized as a 2008 ENERGY STAR Energy Management winner by the U.S. Environmental Protection Agency for the Company’s commitment and dedication to energy efficiency. Allergan has been an ENERGY STAR partner since 1996.
Allergan was presented with The President’s Volunteer Service Award, a U.S. national program that recognizes individuals, families and groups for outstanding community service.